GentiBio closed on a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management. The company also announced exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRK), and MIGAL Galilee Research Institute (MIGAL).
Researchers tested a new drug combo that shows promise for the treatment of the childhood brain cancers diffuse midline gliomas.
Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.
Researchers from Cold Spring Harbor Laboratory in New York discovered that certain proteins believed essential for the survival of cancer cells – the same proteins that many drugmakers have been targeting – may not be as important after all.
Published research shows promise in using Sanofi’s multiple sclerosis drug Aubagio in addition to targeted cancer therapy to treat the aggressive brain cancer glioblastoma.